Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
XOMA Logo
XOMA Growth Score
88
CB Rank
17762
Heat Score
71
XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation.
Acquired by
Ligand Pharmaceuticals Logo
Ligand Pharmaceuticals
Founded
obfuscation
PublicPost-IPO Equity Emeryville, California, United States51-100 xoma.com/
Biotechnology
Developer Platform
Health Care
Therapeutics
Overview

XOMA
Total Funding
obfuscation
Growth Score
88
Heat Score
71

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score88
-8 pts
in past quarter
Heat Score 71
15 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About XOMA

CB Rank
17762
XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation.
Acquired by
Ligand Pharmaceuticals Logo
Ligand Pharmaceuticals
Founded
obfuscation
PublicPost-IPO Equity Emeryville, California, United States51-100 xoma.com/
Biotechnology
Developer Platform
Health Care
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name XOMA Royalty Corporation
Operating Status Active
Number of Exits 
obfuscation
Stock Symbol  NASDAQ:XOMA
Company Type For Profit
Founders  Patrick J. Scannon
About the Company

XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a pioneering proprietary pipeline, a world-class antibody discovery and development platform, plus multiple revenue streams, XOMA is creating innovative human antibody therapeutics with the

potential to transform medicine and reshape people's lives.

Phone Number +1-510-204-7200
Contact Email BizDevInfo@xoma.com
Predictions & Insights

Growth Insight

See this Growth Insight
XOMA is
Lorem
 to be growing
Top Contributing Factors
Financial Growth

Products & Services

XOMA Royalty
A biotech royalty aggregator that acquires economic rights to future milestone and royalty payments from pre-commercial clinical candidates and commercial therapies.
Royalty Portfolio
A collection of licenses providing rights to future potential royalty and milestone payments from drug candidates developed by other companies.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - XOMA Logo
Post-IPO Equity - XOMA
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - XOMA Logo
Post-IPO Equity - XOMA
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - XOMA Logo
Post-IPO Equity - XOMA
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - XOMA Logo
Post-IPO Equity - XOMA
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - XOMA Logo
Post-IPO Equity - XOMA
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - XOMA Logo
Post-IPO Equity - XOMA
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - XOMA Logo
Post-IPO Equity - XOMA
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - XOMA Logo
Post-IPO Equity - XOMA
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - XOMA Logo
Post-IPO Equity - XOMA
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - XOMA Logo
Post-IPO Equity - XOMA
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Blue Owl Logo
Blue Owl
Yes
Post-IPO Debt - XOMA Logo
Post-IPO Debt - XOMA
—
Blue Owl Logo
Blue Owl
Yes
Post-IPO Debt - XOMA Logo
Post-IPO Debt - XOMA
—
Blue Owl Logo
Blue Owl
Yes
Post-IPO Debt - XOMA Logo
Post-IPO Debt - XOMA
—
Blue Owl Logo
Blue Owl
Yes
Post-IPO Debt - XOMA Logo
Post-IPO Debt - XOMA
—
Blue Owl Logo
Blue Owl
Yes
Post-IPO Debt - XOMA Logo
Post-IPO Debt - XOMA
—

Investments

Number of Investments 1
Number of Exits 
obfuscation
Number of Acquisitions 6
See investment data for this company, with details on deal size, industry, stage, and more.
Announced Date  
Organization Name  
Lead Investor  
Funding Round  
Money Raised  
obfuscation
Daré Bioscience Logo
Daré Bioscience
Yes
Post-IPO Debt - Daré Bioscience Logo
Post-IPO Debt - Daré Bioscience
obfuscation
obfuscation
Daré Bioscience Logo
Daré Bioscience
Yes
Post-IPO Debt - Daré Bioscience Logo
Post-IPO Debt - Daré Bioscience
obfuscation
obfuscation
Daré Bioscience Logo
Daré Bioscience
Yes
Post-IPO Debt - Daré Bioscience Logo
Post-IPO Debt - Daré Bioscience
obfuscation
obfuscation
Daré Bioscience Logo
Daré Bioscience
Yes
Post-IPO Debt - Daré Bioscience Logo
Post-IPO Debt - Daré Bioscience
obfuscation
obfuscation
Daré Bioscience Logo
Daré Bioscience
Yes
Post-IPO Debt - Daré Bioscience Logo
Post-IPO Debt - Daré Bioscience
obfuscation

Investment Breakdown

Number of Investments 1
Number of Exits 
obfuscation
Number of Acquisitions 6
See investment data for this company, with details on deal size, industry, stage, and more.
Announced Date  
Organization Name  
Lead Investor  
Funding Round  
Money Raised  
obfuscation
Daré Bioscience Logo
Daré Bioscience
Yes
Post-IPO Debt - Daré Bioscience Logo
Post-IPO Debt - Daré Bioscience
obfuscation
obfuscation
Daré Bioscience Logo
Daré Bioscience
Yes
Post-IPO Debt - Daré Bioscience Logo
Post-IPO Debt - Daré Bioscience
obfuscation
obfuscation
Daré Bioscience Logo
Daré Bioscience
Yes
Post-IPO Debt - Daré Bioscience Logo
Post-IPO Debt - Daré Bioscience
obfuscation
obfuscation
Daré Bioscience Logo
Daré Bioscience
Yes
Post-IPO Debt - Daré Bioscience Logo
Post-IPO Debt - Daré Bioscience
obfuscation
obfuscation
Daré Bioscience Logo
Daré Bioscience
Yes
Post-IPO Debt - Daré Bioscience Logo
Post-IPO Debt - Daré Bioscience
obfuscation

Diversity Investments

Number of Diversity Investments 1
Announced Date  
Organization Name  
Diversity Spotlight  
Funding Round  
Money Raised  
obfuscation
Daré Bioscience Logo
Daré Bioscience
Women Founded
Post-IPO Debt - Daré Bioscience Logo
Post-IPO Debt - Daré Bioscience
obfuscation

M&A Details

XOMA was acquired by Ligand Pharmaceuticals for
obfuscation
on
obfuscation
. This deal was done in Cash.
Transaction Name 
XOMA acquired by Ligand Pharmaceuticals Logo
XOMA acquired by Ligand Pharmaceuticals
Acquired by 
Ligand Pharmaceuticals Logo
Ligand Pharmaceuticals
Announced Date 
obfuscation
Price 
obfuscation
Market Intelligence
People
View Profiles & Contacts
Headcount 51-100 Employee Profiles 4 Board Members and Advisors 5 Contacts 39

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 14, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 13, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 8, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 8, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

4,870
-75.72%
 in past month

IT Spend

$2.2MThis year, XOMA is projected to spend $2.2M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Open Platforms Logo
Open Platforms
96
Financial Close Logo
Financial Close
96
Cambridge, Massachusetts Logo
Cambridge, Massachusetts
95

Actively Used Products

16XOMA uses 16 technology products and services including HTML5, Office 365, and  Microsoft Outlook, according to G2 Stack.

Active Website Tech Count

41XOMA is actively using 41 technologies for its website, according to BuiltWith. These include Viewport Meta, IPhone / Mobile Compatible, and  SSL by Default.

Total IP

128The intellectual property of XOMA includes 117 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, XOMA has registered 11 trademarks with the most popular class being 'Legal services', according to IPqwery.
Sub-Organizations

Sub-Organizations

Number of Sub-Orgs 1
Which industries do these Sub-Organization operate in?
XRA 5 Corp Logo
XRA 5 CorpSubsidiary
Frequently Asked Questions

Where is XOMA's headquarters? XOMA is located in Emeryville, California, United States.Who invested in XOMA? XOMA has 2 investors including Blue Owl and  Novartis.When was the last funding round for XOMA? XOMA closed its last funding round on
obfuscation
from a Post-IPO Equity round.How much funding has XOMA raised to date? XOMA has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(7f45e42 1)
|